Get the Stockscreener App
1.60
5.26%
0.08
After Hours:
1.66
0.06
+3.75%
Biovie Inc stock is traded at $1.60, with a volume of 187.05K.
It is up +5.26% in the last 24 hours and down -80.46% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.52
Open:
$1.54
24h Volume:
187.05K
Relative Volume:
0.76
Market Cap:
$13.08M
Revenue:
-
Net Income/Loss:
$-25.56M
P/E Ratio:
-0.3077
EPS:
-5.2
Net Cash Flow:
$-19.35M
1W Performance:
-3.03%
1M Performance:
-80.46%
6M Performance:
+8.11%
1Y Performance:
-52.10%
1-Day Range:
$1.52
$1.6475
1-Week Range:
$1.46
$1.80
52-Week Range:
$0.62
$9.56
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.60 | 13.08M | 0 | -25.56M | -19.35M | -5.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
BioVie stock dips on pricing $12M securities offering - MSN
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - Amarillo Globe-News
What hedge funds are buying BioVie Inc.Weekly Trade Recap & Real-Time Market Sentiment Reports - mustnews.co.kr
Why Is BioVie Stock (BIVI) Down 50% Today? - MSN
Can BioVie Inc. deliver alphaJuly 2025 Drop Watch & AI Driven Price Predictions - newsimpact.co.kr
Will BioVie Inc. announce a stock split2025 Volatility Report & Stepwise Trade Signal Guides - thegnnews.com
How high can BioVie Inc. stock price go in 2025Earnings Trend Report & Weekly High Conviction Ideas - Newser
Smart tools for monitoring BioVie Inc.’s price action2025 Fundamental Recap & Accurate Trade Setup Notifications - Newser
Understanding BioVie Inc.’s price movementTake Profit & Long-Term Capital Growth Strategies - Newser
BioVie Inc. Presents Phase 2 ADDRESS-LC Trial Design for Bezisterim in Long COVID at Keystone Symposia - Quiver Quantitative
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design - GlobeNewswire
BioVie's Novel Long COVID Drug Trial Targets Brain Fog and Fatigue in 18M+ Americans - Stock Titan
BioVie Completes $10.4 Million Public Offering - The Globe and Mail
BioVie Inc. stock prediction for this weekAI Trend Detection for Entry Timing - Newser
Sector ETF performance correlation with BioVie Inc.Entry and Exit Strategy for Swing Traders - Newser
BioVie Completes $10.4 Million Public Offering to Strengthen Financial Position - AInvest
Has BioVie Inc. found a price floorPortfolio Risk Distribution Analysis Tool - Newser
BioVie closes $12 million public offering of units By Investing.com - Investing.com Canada
BioVie Inc. Announces Closing of $12 Million Public Offering - GlobeNewswire
BioVie Inc. Raises $12 Million Through Public Offering - AInvest
BioVie Secures $12M Financing: Units at $2.00 Include 5-Year Warrants for Drug Development Pipeline - Stock Titan
What machine learning models say about BioVie Inc.Real-Time Setup Summary with ROI Focus - Newser
Why BioVie Inc. stock is on top investor watchlistsReal-Time Investment Picks with Accuracy - Newser
BioVie closes $12 million public offering of units - Investing.com
What is the short-term price target for BIVI according to analyst ratings? - AInvest
Bloomberg to Air New to The Street Episode #683 Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - AInvest
BioVie Inc. Raises $12 Million in Public Offering, Offers Warrants - AInvest
BioVie Prices 6M Share Secondary at $2.00, Below Last Closing Price of $2.91 - AInvest
BioVie Inc. Announces Pricing of $12 Million Public Offering - GlobeNewswire
BioVie (BIVI.O) Crashes 42.78%: What's Behind the Sharp Intraday Move? - AInvest
Biovie stock plunges after pricing $12 million public offering By Investing.com - Investing.com South Africa
Biovie stock plunges after pricing $12 million public offering - Investing.com
S&P 500 Moves Higher; Under Armour Shares Tumble After Q1 Results - Benzinga
BioVie's 45% Plunge: A Capital Raise Gone Wrong? - AInvest
US Stocks Surge as Dow Gains 300 Points, American Axle & Mfg Posts Upbeat Earnings - AInvest
Dow Surges 300 Points; American Axle & Manufacturing Posts Upbeat Earnings - Benzinga
BioVie Announces $12M Securities Offering - AInvest
BioVie's (BIVI) 43% Plunge: A Volatile Turn in the Biotech Arena? - AInvest
BioVie Stock Dips After Share Offering News - timothysykes.com
Why Expedia Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Clinical-Stage Biotech BioVie Secures $12M Financing: Key Details of Stock and Warrant Offering Revealed - Stock Titan
BioVie prices $12 million public offering of units at $2.00 each - Investing.com
Biovie's $12M Equity Raise: Is This a Strategic Lifeline or a Warning Signal for Small-Cap Biotechs? - AInvest
BioVie Inc. Raises $12 Million in Public Offering - AInvest
Biovie announces pricing of $12 million public offering - MarketScreener
Biovie Announces Pricing Of $12 Million Public Offering - TradingView
BioVie Inc. Announces Pricing of $12 Million Public Offering - Benzinga
Real time scanner hits for BioVie Inc. explainedTrading Volume Anomaly Summary and Insight - Newser
What is the risk reward ratio of investing in BioVie Inc. stockHigh-velocity gains - Jammu Links News
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):